Concepedia

Tyler A. Longmire

TA

Statistics

Publications

13

Citations

1.5K

H-Index

13

Active since

2009

Affiliations

Novartis (Switzerland)(Current)

The University of Texas MD Anderson Cancer Center

National Cancer Centre Singapore

Dana-Farber Cancer Institute

The University of Texas at San Antonio Health Science Center

Tyler A. Longmire is an author at Novartis (Switzerland) specializing in cancer immunotherapy, pharmacology, and life sciences.

Publications per year

2009–2023

13

Publications

13

Efficient Derivation of Purified Lung and Thyroid Progenitors from Embryonic Stem Cells

Tyler A. Longmire, Laertis Ikonomou, Finn Hawkins et al. · Cell stem cell · 2012 · 391 citations · Full text

Life Sciences, Cell Biology, Developmental Biology +17

Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors

Giuseppe Curigliano, Hans Gelderblom, Nicolas Mach et al. · Clinical Cancer Research · 2021 · 348 citations · Full text

Pharmacy, Oncology, Pharmacology +17

Excision of Reprogramming Transgenes Improves the Differentiation Potential of iPS Cells Generated with a Single Excisable Vector

Cesar Sommer, Andreia Gianotti Sommer, Tyler A. Longmire et al. · Stem Cells · 2009 · 268 citations · Full text

Life Sciences, Biotechnology, Cell Biology +16

Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies

Patrick Schöffski, Daniel Shao-Weng Tan, Miguel Martín et al. · Journal for ImmunoTherapy of Cancer · 2022 · 156 citations · Full text

Medicine, Oncology, Pharmacology +17

Phase Ib Study of the Anti-TIM-3 Antibody MBG453 in Combination with Decitabine in Patients with High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

Uma Borate, Jordi Esteve, Kimmo Porkka et al. · Blood · 2019 · 85 citations

Medicine, Hematology, Pharmacology +17

1–5 of 13